Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Pushes For Fast-Track Approval Of Flu Treatment Peramivir

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Shionogi announced Sept. 30 it is preparing to submit an application for approval for influenza treatment peramivir for A/H1N1 and other varieties of flu
Advertisement

Related Content

Shionogi Files Early NDA For Flu Drug Peramivir, Aims For 3 Million User Annual Supply
Shionogi Files Early NDA For Flu Drug Peramivir, Aims For 3 Million User Annual Supply
Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota, Japanese Daiichi Sankyo
Positive Phase III Results For Relenza Follow-On Owned By Aussie Biotech Biota, Japanese Daiichi Sankyo
Advertisement
UsernamePublicRestriction

Register

SC070029

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel